The mild influenza epidemic of mixed A and B strains early in I966 provided an opportunity to assess the efficacy of an oil-adjuvant influenza vaccine which had been administered more than two years earlier to I,341 volunteers at two U.K. Atomic Energy Authority establishments. At the 5% confidence level, a statistically significant reduction in sickness absence due to influenza was found in this vaccinated group when compared with a control group of 9I8 employees. This trend was observed at both establishments. Some confirmation was thus obtained of serological predictions that protection would last two to three years or longer after inoculation. There was some indication that the vaccine might be more effective in older workers. This trial suggests the need for more long-term evaluation of oil-adjuvant influenza vaccines.
Hobson, Lane, Beare, and Chivers (I964) found high haemagglutination-inhibiting (H.I.) antibody titres in the sera of almost half their volunteers who had been inoculated with an oil-adjuvant influenza vaccine more than two years previously. The antibody titres which were found suggest that if artificially induced antibodies are as effective as naturally acquired antibodies (a supposition by no means proven), the clinical protection offered by such vaccines may well extend to three years or longer.
Davenport, Hennessy, and Bell (I962) pointed out that, with adjuvant vaccines, antibody levels of from a quarter to a half of the maximum attained have been found eight to nine years after inoculation. Himmelweit (I963) All other respiratory conditions .. 490-93, 5I0-27, 783 national Statistical Classification of the World Health Organization (Table IV) .
Results
All certified sickness absence arising from respiratory causes during the period January i to April 30, i966 was abstracted from routine records maintained on magnetic tape. All episodes for the two groups were included regardless of the duration of absence; the proportion of absences of less than four days' duration was I9% in each group. Only in the influenza group was there a significant difference at the 5 % confidence level between the vaccinated and control groups (Table V) , and this was sufficient to give the vaccinated group a significant advantage when all respiratory episodes were combined ( Table V) . The totals shown in Table V do not equal the sum of the disease groupings, since the groups are not mutually exclusive. People who appear only once in the total may be included in more than one respiratory group. This trend in favour of the vaccinated group was apparent at both Springfields and Dounreay, although the numbers at risk at Springfields yielded results which were rather small for formal tests of significance; for this reason separate tables are not given. The protection rate of about 30% was almost exactly that found in an earlier trial in the Atomic Energy Authority (Meichen, Rogan, and Howell, I962) in an epidemic year. On that occasion, the vaccine was a saline one which had been administered shortly before the outbreak. Another finding common to the I962 report was that the vaccine appeared to be more effective in the older workers (Table VI) The data from previous tables expressed in the conventional industrial manner (Table VII) showed an improvement for the influenza disease group in the vaccinated staff but little real difference otherwise. Once sickness absence had occurred no real effect on the length of absence could be attributed to the vaccine, though it is fair to say that the vaccinated group showed slightly better figures (Table VII) . The variation in the length of absence in the 'other respiratory episodes' group is possibly a reflection of the small numbers involved.
Discussion
Many recent reports (Cook, I965; Howell and Mackenzie, I964; Howell and Stott, i964; Meichen Adjuvant vaccines have at present been withdrawn in this country because of nodule formation in a very small proportion of those inoculated. As these vaccines, perhaps in an improved form, may be back on the market for large-scale prophylaxis, further trials to evaluate the protective period are of some importance.
